Semaglutide GLP-1 is formulated to provide long-lasting appetite control because it is typically administered once per week
The preclinical side effect profile is favorable over 4 weeks: no pathological cardiac hypertrophy (some ERRalpha myocardial effects are physiological, dose is calibrated to remain in the adaptive range), no hepatic toxicity, no mitogenic signal at tested doses
As of March 2026, two trials are actively recruiting new participants: the Maintenance trial (NCT06859268, testing dose reduction after initial weight loss) and a new enrollment trial (NCT07232719, 250 participants with obesity or overweight)
Wolverine Stack (Recovery & Repair): BPC-157 + TB-500 The Wolverine Stack combines localized healing with systemic recovery
and the other, anonymous, reviewer(s) for their contribution to the peer review of this work